- Home
- NTIP vs INKT Comparison
NTIP vs INKT Comparison
Compare NTIP & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- INKT
- Stock Information
- Founded
- NTIP 1990
- INKT 2017
- Country
- NTIP United States
- INKT United States
- Employees
- NTIP N/A
- INKT N/A
- Industry
- NTIP Multi-Sector Companies
- INKT Medicinal Chemicals and Botanical Products
- Sector
- NTIP Miscellaneous
- INKT Health Care
- Exchange
- NTIP Nasdaq
- INKT Nasdaq
- Market Cap
- NTIP 31.9M
- INKT 31.2M
- IPO Year
- NTIP 1998
- INKT 2021
- Fundamental
- Price
- NTIP $1.25
- INKT $7.03
- Analyst Decision
- NTIP
- INKT Strong Buy
- Analyst Count
- NTIP 0
- INKT 2
- Target Price
- NTIP N/A
- INKT $37.50
- AVG Volume (30 Days)
- NTIP 6.5K
- INKT 5.4K
- Earning Date
- NTIP 05-09-2025
- INKT 05-15-2025
- Dividend Yield
- NTIP 8.00%
- INKT N/A
- EPS Growth
- NTIP N/A
- INKT N/A
- EPS
- NTIP N/A
- INKT N/A
- Revenue
- NTIP $250,000.00
- INKT N/A
- Revenue This Year
- NTIP N/A
- INKT N/A
- Revenue Next Year
- NTIP N/A
- INKT N/A
- P/E Ratio
- NTIP N/A
- INKT N/A
- Revenue Growth
- NTIP N/A
- INKT N/A
- 52 Week Low
- NTIP $1.17
- INKT $4.56
- 52 Week High
- NTIP $1.86
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- NTIP 49.78
- INKT 44.59
- Support Level
- NTIP $1.22
- INKT $6.89
- Resistance Level
- NTIP $1.30
- INKT $7.40
- Average True Range (ATR)
- NTIP 0.04
- INKT 0.53
- MACD
- NTIP 0.00
- INKT -0.01
- Stochastic Oscillator
- NTIP 50.00
- INKT 40.59
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.